Your browser is no longer supported. Please, upgrade your browser.
Settings
XBI SPDR S&P Biotech ETF daily Stock Chart
XBI [NYSE]
SPDR S&P Biotech ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-2.71%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month10.37%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter18.83%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio5.10 Perf Half Y23.22%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year6.55%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range44.10 - 73.55 Perf YTD-5.45%
Dividend0.34 P/FCF- EPS past 5Y- ROI- 52W High-9.86% Beta-
Dividend %0.51% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low50.31% ATR1.77
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)53.82 Volatility2.57% 2.57%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.89 Prev Close65.52
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume6.40M Price66.29
Recom- SMA202.20% SMA505.14% SMA20016.35% Volume5,667,223 Change1.18%
Oct-01-16 12:01AM  [$$] How to Play the Next Biotech M&A Surge at Barrons.com
Sep-27-16 10:57AM  Expect More Volatility for Healthcare ETFs
Sep-24-16 01:00AM  [$$] Biotech Is Cheaper Than Big Pharma at Barrons.com
Sep-22-16 11:53AM  Gilead Sciences: Another Blow to R&D Strategy at Barrons.com
Sep-21-16 11:23AM  Biotech ETFs in Focus on Tobira Therapeutics' Massive Gain
10:05AM  Ionis, GlaxoSmithKline Partner on Abnormal Protein Treatment
Sep-20-16 06:05PM  Biotech ETF At Best Level Since January; Are You Braced For Bumps?
05:04PM  How Ioniss Revenue Trends Are Changing
12:37PM  Charting the S&P 500s bullish-leaning holding pattern ahead of the Fed at MarketWatch
12:28PM  Tuesday links: personal well-being
Sep-17-16 11:46AM  The Week Ahead: Should You Care About The 'Bulls No.1 Lie?' at Forbes
Sep-16-16 10:06AM  A Battered Biotech ETF can Rise Again
Sep-15-16 05:42PM  Biotech bright spots
Sep-14-16 03:12PM  A Good Trader Should Be Able to Adjust to Changing Markets
02:19PM  Inside the Recent Surge in Biotech ETFs
Sep-13-16 04:10PM  Applied Genetics stock suffers record plunge to record low at MarketWatch
11:09AM  3 Reasons to Buy Teva Right Now
Sep-12-16 11:53AM  Biotech ETFs: Rallying Because Hillary Clinton Has Pneumonia? at Barrons.com
Sep-09-16 02:04PM  Here Are the Latest Analyst Recommendations for Biogen
Sep-04-16 01:00PM  How Financial Advisors Measure Capital Market Expectations (WFC, BLK) at Investopedia
Sep-02-16 04:04PM  Understanding Incytes Revenue Stream in 2Q16
10:49AM  Clinton's Proposal To Combat Drug Price Hikes
Aug-31-16 03:39PM  Biotech ETF Industry Outlook
11:53AM  Why Eylea Could Face Tough Competition in 2016
10:48AM  Healthcare ETFs Need Some Rest
Aug-30-16 06:04PM  $1 Billion Sales Target in Place for Tyvaso
09:39AM  Biotech ETFs Back In The Spotlight
Aug-29-16 10:43AM  Biotech Stocks: Look Who's Selling at Barrons.com
Aug-26-16 10:27AM  Biotech ETFs in Focus After Mylan's EpiPen Controversy
08:04AM  Could Zinbryta Become a Novel Immunomodulatory Therapy for MS?
Aug-25-16 02:14PM  Clinton Mylan Attack Reminds Biotech ETF Investors of Election Risks
Aug-24-16 02:37PM  How Advisors Evaluate Industry, Sector ETFs
11:04AM  Medivation: The Latest Analyst Recommendations
Aug-23-16 08:16AM  It Could Be An Interesting Ride For Healthcare ETFs
Aug-22-16 12:46PM  Medivation shareholders should be thrilled about price of Pfizer deal: analysts at MarketWatch
Aug-17-16 06:46AM  Healthcare Investors May Be Pricing In A Clinton Victory
Aug-16-16 12:36PM  Charting the U.S. benchmarks pulling-teeth breakout attempt at MarketWatch
11:08AM  Tuesday links: operating in silos
06:07AM  US Consumer Sentiment Is Below the Forecast
Aug-15-16 02:58PM  Bulls are chasing uptrend in biotech fund
11:58AM  Biotech Stocks: The Rebirth of the Bull? at Barrons.com
Aug-11-16 11:58AM  Active Traders Turn Bullish on Biotech at Investopedia
Aug-09-16 10:15AM  Crushed Bio-Tech leader falls 90%, now attempting breakout
Aug-06-16 11:16AM  The Week Ahead: Is Macro Really Wacko? at Forbes
Aug-05-16 09:07AM  Why Markets Remained Range Bound after US Data Release
Aug-04-16 10:00AM  Amid Biotech Rally, Investors Show Jitters
Aug-02-16 05:00PM  Biogen surges on takeover talk. 4 Trades
04:09PM  2 Biotech Funds Leading Nascent Bull Market: Which Is Right For You?
09:08AM  Is BioMarin Set to Become Profitable in 2017?
09:05AM  How Significant Is Alexions Opportunity with Soliris?
07:57AM  Weak US Data: ISM Manufacturing PMI and Construction Spending
06:59AM  Talk about risk on: The unpredictable biotech sector just entered a bull market at MarketWatch
Aug-01-16 12:33PM  Why Did the US Dollar Index Fall Last Week?
12:33PM  Biotech bounce
10:22AM  Investor buys time for a rally in biotechs
Jul-30-16 11:12AM  The Week Ahead: Bull Sheds Sheep's Clothing at Forbes
Jul-29-16 11:58AM  Biotech Stocks: The End of Political Risk? at Barrons.com
11:21AM  Best ETFs of July
Jul-28-16 01:58PM  Celgene Set to Squeeze Short Sellers (CELG, IBB) at Investopedia
09:11AM  FOMC Keeps the Door Open for a Live Meeting in September
07:00AM  A Trump win could also be a win for these volatile stocks at CNBC
Jul-25-16 12:06PM  Yee: Biotech stocks will outperform after election
12:00PM  Bracing for a 'bio-wreck'?
05:00AM  This Week Could Decide Whether Biotech ETFs' Rally Sizzles Or Fizzles
Jul-22-16 01:12PM  Will Orenitram Lose Market Share to Uptravi in 2016?
Jul-21-16 12:00PM  Is biotech back?
Jul-19-16 04:21PM  Earnings Estimates for These 3 Biotech Giants Should Be Heading Lower -- Here's Why at Motley Fool
Jul-18-16 11:07AM  How Much Potential Does Promacta Hold?
Jul-14-16 01:11PM  Ligand Pharmaceuticalss Performance Based on EV-to-EBITDA
11:05AM  ALNY Reports Positive Results from Open Label Extension Study of Revusiran
Jul-13-16 02:35PM  New Stock Market Highs Fighting Many More Outside Pressures Than Usual: Time to Panic? at 24/7 Wall St.
09:00AM  Biotech ETFs: Will the Once Hot Group Rebound?
Jul-07-16 12:18PM  Strong ISM Non-Manufacturing PMI Overshadows Services PMI
Jul-05-16 11:05AM  AbbVies Tests of Imbruvica with Venclexta for Oncology Therapy
Jul-01-16 04:06PM  Biotech Bottom Calls After Big Bounce (IBB, XBI) at Investopedia
11:07AM  What Are the Benefits of the Novartis-Xencor Alliance to Xencor?
07:01AM  Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here
Jun-30-16 06:33PM  Biotechs Building Base?...Or Bursting Bubble?
03:54PM  How Did Investors Respond to the Novartis-Xencor Alliance?
03:54PM  The Novartis-Xencor Collaboration Agreement: The Details
02:21PM  Hedge Funds Like ETFs Too
08:21AM  US Inflation Numbers Are Decent, Brexit Clouds Future Outlook
Jun-29-16 07:00AM  US GDP and Consumer Confidence: Is a Revival Coming?
Jun-26-16 07:21AM  The 5 Best Healthcare ETFs at Motley Fool
Jun-24-16 09:56AM  Brexit means little for biotech stocks, analyst says at MarketWatch
Jun-22-16 02:07PM  Traders Get It Right (Sort Of) With Leveraged Biotech ETFs
Jun-21-16 01:09PM  Bio Tech; Market leader testing breakdown level
Jun-16-16 10:46AM  Why Does XBIs Loss Continue to Widen?
Jun-15-16 11:50AM  Biotech: It's the Election, Silly at Barrons.com
09:16AM  Cellectar's stock soars after positive results of a study of its tumor treatment at MarketWatch
Jun-14-16 03:32PM  Biotech: Still Troubled at Barrons.com
07:00AM  IBB & XBI: Should You Short the Biotech Industry? at Investopedia
Jun-13-16 02:00PM  3 Cases When Not to Place Tight Stop-Loss Orders (IBB, XBI) at Investopedia
09:06AM  How Are XBIs Holdings Moving Averages Trending?
Jun-10-16 03:58PM  Downside Ahead For Biotech Stocks?
Jun-07-16 12:44PM  Yellen Upbeat on Economy: Wining Sector ETFs
12:33AM  Biotech Bounce: Sizzle Or Fizzle?
Jun-06-16 03:34PM  How Did Biotech ETFs Perform in the Week Ended June 3?
07:47AM  Exelixis's stock surges after positive results from trial of kidney cancer treatment at MarketWatch
Jun-03-16 01:20PM  The buzz from ASCO
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.